ABIOMED, Inc. (ABMD) Shares Bought by Penserra Capital Management LLC

Penserra Capital Management LLC grew its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 37.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,554 shares of the medical equipment provider’s stock after buying an additional 13,745 shares during the quarter. ABIOMED accounts for approximately 1.4% of Penserra Capital Management LLC’s holdings, making the stock its 13th largest position. Penserra Capital Management LLC owned approximately 0.11% of ABIOMED worth $22,736,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABMD. MERIAN GLOBAL INVESTORS UK Ltd lifted its holdings in shares of ABIOMED by 1,030.0% during the 3rd quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 638,856 shares of the medical equipment provider’s stock valued at $287,325,000 after buying an additional 582,318 shares during the period. Renaissance Technologies LLC raised its holdings in ABIOMED by 35.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,551,423 shares of the medical equipment provider’s stock worth $634,610,000 after purchasing an additional 401,800 shares during the period. FMR LLC raised its holdings in ABIOMED by 34.2% in the 2nd quarter. FMR LLC now owns 691,818 shares of the medical equipment provider’s stock worth $282,988,000 after purchasing an additional 176,394 shares during the period. Carillon Tower Advisers Inc. raised its holdings in ABIOMED by 77.0% in the 2nd quarter. Carillon Tower Advisers Inc. now owns 400,348 shares of the medical equipment provider’s stock worth $163,762,000 after purchasing an additional 174,198 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. bought a new position in ABIOMED in the 2nd quarter worth $58,965,000. 87.14% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:ABMD opened at $412.10 on Thursday. The stock has a market cap of $17.50 billion, a price-to-earnings ratio of 168.20, a price-to-earnings-growth ratio of 3.18 and a beta of 0.35. ABIOMED, Inc. has a 52 week low of $186.72 and a 52 week high of $459.75.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.36. The business had revenue of $181.78 million for the quarter, compared to analysts’ expectations of $175.41 million. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The business’s quarterly revenue was up 36.9% on a year-over-year basis. During the same period last year, the firm earned $0.54 earnings per share. On average, equities research analysts predict that ABIOMED, Inc. will post 3.57 EPS for the current year.

A number of equities analysts recently commented on ABMD shares. ValuEngine cut ABIOMED from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 18th. BidaskClub cut ABIOMED from a “buy” rating to a “hold” rating in a report on Tuesday, July 31st. Morgan Stanley raised their target price on ABIOMED from $370.00 to $396.00 and gave the stock an “equal weight” rating in a report on Thursday, October 11th. Zacks Investment Research cut ABIOMED from a “buy” rating to a “hold” rating in a report on Tuesday, July 31st. Finally, BTIG Research raised ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 target price on the stock in a report on Friday, November 2nd. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $402.78.

In other ABIOMED news, VP Michael G. Howley sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total transaction of $4,325,000.00. Following the sale, the vice president now directly owns 48,954 shares of the company’s stock, valued at $21,172,605. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Andrew J. Greenfield sold 4,440 shares of the firm’s stock in a transaction dated Wednesday, August 29th. The shares were sold at an average price of $395.00, for a total value of $1,753,800.00. The disclosure for this sale can be found here. 3.50% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “ABIOMED, Inc. (ABMD) Shares Bought by Penserra Capital Management LLC” was reported by WKRB News and is owned by of WKRB News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.wkrb13.com/2018/11/09/abiomed-inc-abmd-shares-bought-by-penserra-capital-management-llc.html.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Story: How much money do you need to begin day trading?

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply